<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509365</url>
  </required_header>
  <id_info>
    <org_study_id>03 PID 11</org_study_id>
    <nct_id>NCT01509365</nct_id>
  </id_info>
  <brief_title>Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27</brief_title>
  <acronym>PLATO-dose</acronym>
  <official_title>Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether administration of 150 mg clopidogrel is
      effective in reducing the one-year incidence of thromboischemic events in patients with high
      on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population
      overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to evaluate the effect of the double maintenance dose of clopidogrel versus
      single dose in patients with proven coronary and with BMI ≥ 27 kg.m-2 1 - Biologically: study
      and compare the respective effects of the double dose and single dose of clopidogrel on
      platelet aggregation.

      2 - Clinically: to study and compare the cardiovascular events and adverse effects depending
      on the dose of clopidogrel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADP-induced platelet aggregation assessed by VerifyNow test</measure>
    <time_frame>7 days after selection of patients</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>sensible</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>simple dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.</description>
    <arm_group_label>double dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.</description>
    <arm_group_label>simple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female,

          -  Old (e) of more than 20 years

          -  BMI ≥ 27kg.m-2

          -  Patients hospitalized for acute coronary syndrome (Whatever the ST segment and
             troponin dosage)

          -  Patients with proven coronary candidates for treatment with Clopidogrel (who received
             a loading dose of 600mg over 2 hours or treated with 75 mg/day or 150mg / day of
             clopidogrel for longer than 7 days)

        Exclusion Criteria:

          -  Patients unwilling.

          -  Patient participating in another study.

          -  Patients with cardiogenic shock

          -  Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability

          -  Patients scheduled for surgery in less than 6 months

          -  ischemic stroke older than 6 weeks.

          -  History of hemorrhagic stroke (any time)

          -  Patients on or candidates for AVK

          -  Patients with a different anti ADP (ticlopidine, prasugrel)

          -  Patients with an indication against clopidogrel (side effects, bleeding ...)

          -  Thrombocytopenia &lt; 100000/mm3

          -  anemia (Ht &lt; 30%)

          -  Thrombocythaemia (Ht &gt; 52%)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faouzi Maatouk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>hospital Fattouma Bourguiba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khaldoun Ben Hamda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Fattouma Bourguiba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Hamdi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Fattouma Bourguiba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Hassine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Fattouma Bourguiba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>cardiology department, hospital Fattouma Bourguiba</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>maintenance dose</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>overweight</keyword>
  <keyword>antiplatelet agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

